Target- |
MechanismImmunomodulators |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Unknown statusNot Applicable A PILOT STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND EFFICACY OF A DAILY DOSE OF 500MG. LU901 (4PHENYL-BUTYRATE, CONTROLLED RELEASE TABLETS) IN ADDITION TO STANDARD HORMONAL TREATMENT IN PATIENTS WITH METASTASIZED PROSTATE CARCINOMA AND A LIFE EXPECTANCY OF AT LEAST 6 MONTHS.
100 Clinical Results associated with Lunamed Operations AG
0 Patents (Medical) associated with Lunamed Operations AG
100 Deals associated with Lunamed Operations AG
100 Translational Medicine associated with Lunamed Operations AG